Nifedipine
Procardia (nifedipine) is a small molecule pharmaceutical. Nifedipine was first approved as Procardia on 1982-01-01. It is used to treat hypertension, stable angina, and variant angina pectoris in the USA. It is known to target voltage-dependent L-type calcium channel subunit alpha-1C, voltage-dependent L-type calcium channel subunit alpha-1D, potassium voltage-gated channel subfamily A member 5, glycine receptor subunit alpha-1, nuclear receptor subfamily 1 group I member 2, transient receptor potential cation channel subfamily M member 3, glycine receptor subunit alpha-3, glycine receptor subunit beta, voltage-dependent L-type calcium channel subunit alpha-1F, voltage-dependent L-type calcium channel subunit alpha-1S, potassium voltage-gated channel subfamily C member 1, potassium voltage-gated channel subfamily A member 7, potassium voltage-gated channel subfamily A member 2, and potassium voltage-gated channel subfamily A member 1.
Download report
Favorite
Searched
Top 200 Pharmaceuticals by Retail Sales
Commercial
Trade Name
FDA
EMA
Procardia (generic drugs available since 1990-09-20, discontinued: Adalat, Afeditab)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| adalat cc | New Drug Application | 2014-05-14 |
| afeditab | ANDA | 2016-08-06 |
| nifedipine | ANDA | 2023-06-16 |
| procardia | New Drug Application | 2019-12-16 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C07: Beta-adrenergic blocking agents
— C07F: Beta blocking agents, other combinations
— C07FB: Beta blocking agents and calcium channel blockers
— C07FB03: Atenolol and nifedipine
— C08: Calcium channel blockers
— C08C: Selective calcium channel blockers with mainly vascular effects
— C08CA: Dihydropyridine derivative selective calcium channel blockers with mainly vascular effects
— C08CA05: Nifedipine
— C08CA55: Nifedipine, combinations
— C08G: Calcium channel blockers and diuretics
— C08GA: Calcium channel blockers and diuretics
— C08GA01: Nifedipine and diuretics
HCPCS
No data
Clinical
Clinical Trials
135 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | 2 | 5 | 9 | 16 | 8 | 37 |
| Premature obstetric labor | D007752 | O60 | 1 | 5 | 6 | 4 | 9 | 22 | |
| Pregnancy-induced hypertension | D046110 | O13 | — | — | 1 | 10 | — | 11 | |
| Pre-eclampsia | D011225 | EFO_0000668 | O14 | 3 | 1 | 1 | 5 | 2 | 11 |
| Essential hypertension | D000075222 | I10 | 2 | 1 | — | 2 | — | 5 | |
| Premature birth | D047928 | EFO_0003917 | O60 | — | — | — | 2 | 2 | 4 |
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | — | — | 1 | — | 1 |
| Altitude sickness | D000532 | EFO_1000782 | T70.29 | — | — | — | 1 | — | 1 |
| Postpartum period | D049590 | — | — | — | 1 | — | 1 | ||
| Urinary calculi | D014545 | N20.9 | — | — | — | 1 | — | 1 |
Show 6 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Diabetic nephropathies | D003928 | EFO_0000401 | — | — | 2 | — | — | 2 | |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | 2 | — | — | 2 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | 2 | — | — | 2 |
| Raynaud disease | D011928 | EFO_1001145 | I73.0 | 1 | — | 1 | — | — | 2 |
| Placenta previa | D010923 | EFO_0007442 | O44 | — | 1 | 1 | — | — | 2 |
| Fissure in ano | D005401 | HP_0012390 | K60.2 | 1 | 2 | 1 | — | — | 2 |
| Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | — | — | 1 | — | — | 1 |
| Coronary disease | D003327 | — | — | 1 | — | — | 1 | ||
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | 1 | — | — | 1 |
| Kidney calculi | D007669 | EFO_0004253 | N20.0 | — | — | 1 | — | — | 1 |
Show 6 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic renal insufficiency | D051436 | N18 | 1 | 2 | — | — | 1 | 4 | |
| Proteinuria | D011507 | HP_0000093 | R80 | 2 | 2 | — | — | — | 3 |
| Cognitive dysfunction | D060825 | G31.84 | — | 1 | — | — | — | 1 | |
| Aging | D000375 | GO_0007568 | R41.81 | — | 1 | — | — | — | 1 |
| Blood pressure | D001794 | EFO_0004325 | — | 1 | — | — | — | 1 | |
| Epilepsy | D004827 | EFO_0000474 | G40.9 | — | 1 | — | — | — | 1 |
| Partial epilepsies | D004828 | EFO_0004263 | — | 1 | — | — | — | 1 | |
| Embryo implantation | D010064 | — | 1 | — | — | — | 1 | ||
| Congenital adrenal hyperplasia | D000312 | E25.0 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 3 | — | — | — | — | 3 | ||
| Therapeutic equivalency | D013810 | 2 | — | — | — | — | 2 | ||
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | — | — | — | — | 1 |
| Morbid obesity | D009767 | EFO_0001074 | 1 | — | — | — | — | 1 | |
| Systemic scleroderma | D012595 | EFO_0000717 | M34 | 1 | — | — | — | — | 1 |
| Dermatomyositis | D003882 | EFO_0000398 | M33 | 1 | — | — | — | — | 1 |
| Systemic lupus erythematosus | D008180 | EFO_0002690 | M32 | 1 | — | — | — | — | 1 |
| Thalassemia | D013789 | EFO_1001996 | D56 | 1 | — | — | — | — | 1 |
| Iron overload | D019190 | 1 | — | — | — | — | 1 | ||
| Hemochromatosis | D006432 | EFO_1000642 | E83.11 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pulmonary edema | D011654 | EFO_1001134 | J81 | — | — | — | — | 2 | 2 |
| Regional blood flow | D012039 | — | — | — | — | 1 | 1 | ||
| Ocular physiological phenomena | D009799 | — | — | — | — | 1 | 1 | ||
| Pregnancy rate | D018873 | — | — | — | — | 1 | 1 | ||
| Low cardiac output | D002303 | — | — | — | — | 1 | 1 | ||
| High cardiac output | D016534 | — | — | — | — | 1 | 1 | ||
| Drug-related side effects and adverse reactions | D064420 | T88.7 | — | — | — | — | 1 | 1 | |
| Hypoxia | D000860 | R09.02 | — | — | — | — | 1 | 1 | |
| Continuous positive airway pressure | D045422 | — | — | — | — | 1 | 1 | ||
| Hemangioendothelioma | D006390 | — | — | — | — | 1 | 1 |
Show 4 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | NIFEDIPINE |
| INN | nifedipine |
| Description | Nifedipine is a dihydropyridine, a methyl ester and a C-nitro compound. It has a role as a calcium channel blocker, a vasodilator agent, a tocolytic agent and a human metabolite. |
| Classification | Small molecule |
| Drug class | phenylpyridine vasodilators; tricyclic compounds |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-] |
Identifiers
| PDB | — |
| CAS-ID | 21829-25-4 |
| RxCUI | 7417 |
| ChEMBL ID | CHEMBL193 |
| ChEBI ID | 7565 |
| PubChem CID | 4485 |
| DrugBank | DB01115 |
| UNII ID | I9ZF7L6G2L (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
CACNA1C
CACNA1C
CACNA1D
CACNA1D
KCNA5
KCNA5
GLRA1
GLRA1
NR1I2
NR1I2
TRPM3
TRPM3
GLRA3
GLRA3
GLRB
GLRB
CACNA1F
CACNA1F
CACNA1S
CACNA1S
KCNC1
KCNC1
KCNA7
KCNA7
KCNA2
KCNA2
KCNA1
KCNA1
Organism
Homo sapiens
Gene name
CACNA1C
Gene synonyms
CACH2, CACN2, CACNL1A1, CCHL1A1
NCBI Gene ID
Protein name
voltage-dependent L-type calcium channel subunit alpha-1C
Protein synonyms
CACNA1C intronic transcript 2, CACNA1C intronic transcript 2 (non-protein coding), calcium channel, cardic dihydropyridine-sensitive, alpha-1 subunit, Calcium channel, L type, alpha-1 polypeptide, isoform 1, cardiac muscle, calcium channel, voltage-dependent, L type, alpha 1C subunit, DHPR, alpha-1 subunit, voltage-dependent L-type Ca2+ channel alpha 1 subunit, Voltage-gated calcium channel subunit alpha Cav1.2
Uniprot ID
Mouse ortholog
Cacna1c (12288)
voltage-dependent L-type calcium channel subunit alpha-1C (Q99242)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 25,240 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
89,744 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more